Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Paul Fanta

    TitleAssociate Clinical Professor
    SchoolUniversity of California, San Diego
    Address9500 Gilman Drive #0987
    CA La Jolla 92093
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Research Interests
      The diagnosis and management of gastrointestinal cancers has dramatically changed in the past several years. By incorporating biotechnology, bioinformatics, molecular biomarker analyses, pharmocogenomic data, in the setting of prospective clinical trials, we may better identify patients who will benefit from chemotherapy, avoid toxicities from treatment, and develop a predictive therapeutic strategy unique to a patient’s disease. Enrollment of patients with cancers of the colon, rectum, anus, stomach, esophagus, GI stromal tumors, hepatocellular carcinoma, pancreas, gall-bladder, and cholangiocarcinoma into our clinical trials is a priority.

      Education & Training
      BS - Biology/Chemistry/Math, University of Arizona - 1983
      MS - Microbiology/Immunology, University of Arizona - 2001
      MD - University of Arizona - 2001
      Resident - Scripps-Green Hospital, La Jolla, CA - 2001-2004
      Fellowship - Hematology-Oncology, Scripps Clinic, La Jolla, CA - 2004-2007

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Bieg-Bourne CC, Millis SZ, Piccioni DE, Fanta P, Goldberg ME, Chmielecki J, Parker BA, Kurzrock R. Next-generation sequencing in the clinical setting clarifies patient characteristics and potential actionability. Cancer Res. 2017 Sep 22. PMID: 28939679.
        View in: PubMed
      2. Schwaederle M, Chattopadhyay R, Kato S, Fanta P, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. Cancer Res. 2017 Aug 14. PMID: 28807936.
        View in: PubMed
      3. Fero KE, Coe TM, Fanta P, Tang CM, Murphy JD, Sicklick JK. Surgical Management of Adolescents and Young Adults With Gastrointestinal Stromal Tumors: A US Population-Based Analysis. JAMA Surg. 2017 May 01; 152(5):443-451. PMID: 28114506.
        View in: PubMed
      4. Alkhuziem M, Burgoyne AM, Fanta P, Tang CM, Sicklick JK. The Call of "The Wild"-Type GIST: It's Time for Domestication. J Natl Compr Canc Netw. 2017 May; 15(5):551-554. PMID: 28476734.
        View in: PubMed
      5. Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, Corless CL, Hong D, Fero KE, Murphy JD, Fanta P, Ali SM, De Siena M, Burgoyne AM, Movva S, Madlensky L, Heestand GM, Trent JC, Kurzrock R, Morosini D, Ross JS, Harismendy O, Sicklick JK. FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. J Transl Med. 2016 Dec 14; 14(1):339. PMID: 27974047.
        View in: PubMed
      6. Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Korn WM, Leong S, Linn C, Lockhart AC, Ly QP, Mulcahy MF, Orringer MB, Perry KA, Poultsides GA, Scott WJ, Strong VE, Washington MK, Weksler B, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Oct; 14(10):1286-1312. PMID: 27697982.
        View in: PubMed
      7. Lopez NE, Weiss AC, Robles J, Fanta P, Ramamoorthy SL. A systematic review of clinically available gene expression profiling assays for stage II colorectal cancer: initial steps toward genetic staging. Am J Surg. 2016 Oct; 212(4):700-714. PMID: 27637150.
        View in: PubMed
      8. Sicklick JK, Fanta P, Shimabukuro K, Kurzrock R. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. Cancer Metastasis Rev. 2016 06; 35(2):263-75. PMID: 26857926; PMCID: PMC4912391 [Available on 06/01/17].
      9. Schwaederle M, Husain H, Fanta P, Piccioni DE, Kesari S, Schwab RB, Patel SP, Harismendy O, Ikeda M, Parker BA, Kurzrock R. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clin Cancer Res. 2016 Nov 15; 22(22):5497-5505. PMID: 27185373.
        View in: PubMed
      10. Coe TM, Fero KE, Fanta P, Mallory RJ, Tang CM, Murphy JD, Sicklick JK. Population-Based Epidemiology and Mortality of Small Malignant Gastrointestinal Stromal Tumors in the USA. J Gastrointest Surg. 2016 Jun; 20(6):1132-40. PMID: 27025710; PMCID: PMC4880518 [Available on 06/01/17].
      11. Schwaederle M, Husain H, Fanta P, Piccioni DE, Kesari S, Schwab RB, Banks KC, Lanman RB, Talasaz A, Parker BA, Kurzrock R. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget. 2016 Mar 01; 7(9):9707-17. PMID: 26848768; PMCID: PMC4891078.
      12. Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta P, Lippman SM, Kurzrock R. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther. 2016 Apr; 15(4):743-52. PMID: 26873727.
        View in: PubMed
      13. Patel SP, Schwaederle M, Daniels GA, Fanta P, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. 2015 Oct 20; 6(32):32602-9. PMID: 26418953; PMCID: PMC4741715.
      14. O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Leichman L, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol. 2015 Sep; 26(9):1923-9. PMID: 26091808; PMCID: PMC4551155.
      15. Choueiri MB, Shen JP, Gross AM, Huang JK, Ideker T, Fanta P. ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer. PLoS One. 2015; 10(6):e0126898. PMID: 26083491; PMCID: PMC4470586.
      16. Parish A, Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, Shimabukuro K, Parker BA, Helsten T, Kurzrock R. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. Cell Cycle. 2015; 14(13):2121-8. PMID: 25950492; PMCID: PMC4614941.
      17. Schwaederle M, Daniels GA, Piccioni DE, Fanta P, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. Mol Cancer Ther. 2015 Jun; 14(6):1488-94. PMID: 25852059.
        View in: PubMed
      18. Schwaederlé M, Daniels GA, Piccioni DE, Fanta P, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. Cyclin alterations in diverse cancers: Outcome and co-amplification network. Oncotarget. 2015 Feb 20; 6(5):3033-42. PMID: 25596748; PMCID: PMC4413635.
      19. Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, Das P, Denlinger C, Fanta P, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Jasperson K, Keswani RN, Kleinberg LR, Korn WM, Leong S, Lockhart AC, Mulcahy MF, Orringer MB, Posey JA, Poultsides GA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Washington MK, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw. 2015 Feb; 13(2):194-227. PMID: 25691612.
        View in: PubMed
      20. Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015 Jan; 13(1):78-108. PMID: 25583772.
        View in: PubMed
      21. Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. Cell Cycle. 2015; 14(8):1252-9. PMID: 25695927; PMCID: PMC4614867.
      22. Schwaederle M, Daniels GA, Piccioni DE, Kesari S, Fanta P, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer. Cell Cycle. 2015; 14(11):1730-7. PMID: 25928476; PMCID: PMC4614790.
      23. Scott BJ, van Vugt VA, Rush T, Brown T, Chen CC, Carter BS, Schwab R, Fanta P, Helsten T, Bazhenova L, Parker B, Pingle S, Saria MG, Brown BD, Piccioni DE, Kesari S. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. J Neurooncol. 2014 Sep; 119(2):361-8. PMID: 24942463.
        View in: PubMed
      24. Schwaederle M, Parker BA, Schwab RB, Fanta P, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC, Ojeda-Fournier H, Datnow B, Webster NJ, Lippman SM, Kurzrock R. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. Oncologist. 2014 Jun; 19(6):631-6. PMID: 24797821; PMCID: PMC4041669.
      25. Fanta P, Sicklick JK, Betz BL, Peterson MR. In vivo imatinib sensitivity in a patient with GI stromal tumor bearing a PDGFRA deletion DIM842-844. J Clin Oncol. 2015 Mar 10; 33(8):e41-4. PMID: 24638008; PMCID: PMC4884274.
      26. Simpson DR, Martínez ME, Gupta S, Hattangadi-Gluth J, Mell LK, Heestand G, Fanta P, Ramamoorthy S, Le QT, Murphy JD. Racial disparity in consultation, treatment, and the impact on survival in metastatic colorectal cancer. J Natl Cancer Inst. 2013 Dec 04; 105(23):1814-20. PMID: 24231453; PMCID: PMC4383284.
      27. Mahta A, Kim RY, Fanta P, Lawson JD, Kesari S. Leptomeningeal Metastasis from Appendiceal Adenocarcinoma: Case Report and Literature Review. J Gastrointest Cancer. 2012 Sep; 43 Suppl 1:108-10. PMID: 21826409.
        View in: PubMed
      28. Liang Y, Bydder M, Yashar CM, Rose BS, Cornell M, Hoh CK, Lawson JD, Einck J, Saenz C, Fanta P, Mundt AJ, Bydder GM, Mell LK. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):406-14. PMID: 22687195.
        View in: PubMed
      29. Canepa M, Fanta P, Weidner N, Peterson MR. Schistosomiasis and signet ring cell carcinoma of the rectum. Ann Diagn Pathol. 2012 Oct; 16(5):385-7. PMID: 21546296.
        View in: PubMed
      30. Lawson JD, Sicklick JK, Fanta P. Gastric cancer. Curr Probl Cancer. 2011 May-Jun; 35(3):97-127. PMID: 21635986.
        View in: PubMed
      31. Fanta P, Saven A. Hairy cell leukemia. Cancer Treat Res. 2008; 142:193-209. PMID: 18283787.
        View in: PubMed
      32. Taylor CW, Dorr RT, Fanta P, Hersh EM, Salmon SE. A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2001; 47(1):83-8. PMID: 11221967.
        View in: PubMed
      33. Scott KM, Fanta P, Calaluce R, Dalkin B, Weinstein RS, Nagle RB. Diagnostic frozen prostate sextant biopsies: an approach for preserving protein and RNA for additional studies. Prostate. 2000 Sep 01; 44(4):296-302. PMID: 10951494.
        View in: PubMed
      34. Monk BJ, Alberts DS, Burger RA, Fanta P, Hallum AV, Hatch KD, Salmon SE. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers. Gynecol Oncol. 1998 Nov; 71(2):308-12. PMID: 9826477.
        View in: PubMed
      35. Alberts DS, Fanta P, Running KL, Adair LP, Garcia DJ, Liu-Stevens R, Salmon SE. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers. Cancer Chemother Pharmacol. 1997; 39(6):493-7. PMID: 9118460.
        View in: PubMed
      36. Federico M, Alberts DS, Garcia DJ, Emerson J, Fanta P, Liu R, Salmon SE. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome. Gynecol Oncol. 1994 Dec; 55(3 Pt 2):S156-63. PMID: 7835801.
        View in: PubMed
      37. Taylor CW, Lui R, Fanta P, Salmon SE. Effects of suramin on in vitro growth of fresh human tumors. J Natl Cancer Inst. 1992 Apr 01; 84(7):489-94. PMID: 1545438.
        View in: PubMed